MedKoo Cat#: 555855 | Name: BCI inhibitor
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BCI is an allosteric inhibitor of dual specificity phosphatase (DUSP). BCI specifically inhibits DUSP6 and DUSP1 with EC50s of 13.3 and 8.0 μM in cells, respectively.

Chemical Structure

BCI inhibitor
BCI inhibitor
CAS#1245792-51-1 (E)

Theoretical Analysis

MedKoo Cat#: 555855

Name: BCI inhibitor

CAS#: 1245792-51-1 (E)

Chemical Formula: C22H23NO

Exact Mass: 317.1780

Molecular Weight: 317.43

Elemental Analysis: C, 83.24; H, 7.30; N, 4.41; O, 5.04

Price and Availability

Size Price Availability Quantity
200mg USD 1,150.00 2 Weeks
500mg USD 1,950.00 2 Weeks
1g USD 2,950.00 2 Weeks
2g USD 5,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
Synonym
BCI; (E)-BCI, BCI inhibitor;
IUPAC/Chemical Name
(E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one
InChi Key
XJDKPLZUXCIMIS-HMMYKYKNSA-N
InChi Code
InChI=1S/C22H23NO/c24-22-19-14-8-7-13-18(19)21(23-17-11-5-2-6-12-17)20(22)15-16-9-3-1-4-10-16/h1,3-4,7-10,13-15,17,21,23H,2,5-6,11-12H2/b20-15+
SMILES Code
O=C1/C(C(C2=C1C=CC=C2)NC3CCCCC3)=C/C4=CC=CC=C4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Dual specificity phosphatase 6 (DUSP6) functions as a feedback attenuator of fibroblast growth factor signaling during development.
Product Data
Biological target:
BCI is an inhibitor of dual specificity phosphatase (DUSP) which inhibits DUSP6 and DUSP1 with EC50s of 13.3 and 8.0 μM, respectively.
In vitro activity:
BCI hydrochloride (BCI), a DUSP6 small molecule inhibitor, increased the activity of ERK but interestingly decreased the expression of ERK response genes in BGC823, SGC7901 and CDDP-resistant SGC7901/DDP cells. BCI also caused cell death through the DNA damage response (DDR) pathway. Moreover, BCI inhibited cell proliferation, migration and invasion in a receptor-independent manner and enhanced CDDP cytotoxicity at pharmacological concentrations in the gastric cancer (GC) cells. Reference: Cancer Lett. 2018 Jan 1;412:243-255. https://www.sciencedirect.com/science/article/pii/S0304383517306316?via%3Dihub
In vivo activity:
In vivo experiments showed that BCI enhances the antitumor effects of CDDP (cisplatin) in cell-based xenografts and PDX models. Reference: Cancer Lett. 2018 Jan 1;412:243-255. https://www.sciencedirect.com/science/article/pii/S0304383517306316?via%3Dihub
Solvent mg/mL mM
Solubility
DMSO 125.0 393.79
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 317.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Wu QN, Liao YF, Lu YX, Wang Y, Lu JH, Zeng ZL, Huang QT, Sheng H, Yun JP, Xie D, Ju HQ, Xu RH. Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance. Cancer Lett. 2018 Jan 1;412:243-255. doi: 10.1016/j.canlet.2017.10.007. Epub 2017 Oct 16. PMID: 29050982. 2. Zhang F, Tang B, Zhang Z, Xu D, Ma G. DUSP6 Inhibitor (E/Z)-BCI Hydrochloride Attenuates Lipopolysaccharide-Induced Inflammatory Responses in Murine Macrophage Cells via Activating the Nrf2 Signaling Axis and Inhibiting the NF-κB Pathway. Inflammation. 2019 Apr;42(2):672-681. doi: 10.1007/s10753-018-0924-2. PMID: 30506106.
In vitro protocol:
1. Wu QN, Liao YF, Lu YX, Wang Y, Lu JH, Zeng ZL, Huang QT, Sheng H, Yun JP, Xie D, Ju HQ, Xu RH. Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance. Cancer Lett. 2018 Jan 1;412:243-255. doi: 10.1016/j.canlet.2017.10.007. Epub 2017 Oct 16. PMID: 29050982. 2. Zhang F, Tang B, Zhang Z, Xu D, Ma G. DUSP6 Inhibitor (E/Z)-BCI Hydrochloride Attenuates Lipopolysaccharide-Induced Inflammatory Responses in Murine Macrophage Cells via Activating the Nrf2 Signaling Axis and Inhibiting the NF-κB Pathway. Inflammation. 2019 Apr;42(2):672-681. doi: 10.1007/s10753-018-0924-2. PMID: 30506106.
In vivo protocol:
1. Wu QN, Liao YF, Lu YX, Wang Y, Lu JH, Zeng ZL, Huang QT, Sheng H, Yun JP, Xie D, Ju HQ, Xu RH. Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance. Cancer Lett. 2018 Jan 1;412:243-255. doi: 10.1016/j.canlet.2017.10.007. Epub 2017 Oct 16. PMID: 29050982.
[1]. Korotchenko VN, et al. In vivo structure-activity relationship studies support allosteric targeting of a dual specificity phosphatase. Chembiochem. 2014 Jul 7;15(10):1436-45.